Drug Type Biological products |
Synonyms mANP, ZD-100 |
Target |
Mechanism Aldosterone antagonists |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Resistant hypertension | Phase 2 | US | 17 Nov 2024 | |
Chronic Kidney Diseases | Phase 2 | US | 04 Nov 2022 | |
Heart failure with normal ejection fraction | Phase 2 | US | 04 Nov 2022 |
Phase 1 | 36 | kdqtwaiapr(ycdgipzfki) = There were no reported drug related serious adverse events dwzfmsaupz (vcevurbjxy ) View more | Positive | 30 Aug 2024 | |||
Placebo | |||||||
Phase 1 | 22 | fxpkdrbnob(mcyjrclxho) = rpenfkiukc hxieirdsmo (zuonqqegym ) View more | - | 26 Aug 2023 | |||
Phase 1 | - | ozqyazycec(xxzbhgofkq) = dbelgerwon aiksmghttw (umzjtzvpjw ) View more | - | 28 Aug 2016 | |||
Placebo | rlwiwabatg(xfpmqoqbfy) = hvpdjziqey wxrnntwxyj (nibaedbuvu ) View more |